Christopher Thompson, PA
Medical · Spartanburg, SCNPI 1942544119
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by AbbVie at 34.0% of the total. 2025 is the largest year on record at $36,749, more than ten times the $2,494 reported in 2021. Among medical clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,342 payments — averaging $57.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$26K
- UCB, Inc.$23K
- Pfizer$5K
- Arcutis Biotherapeutics, Inc.$4K
- Johnson & Johnson$3K
- Sun Pharmaceutical Industries Inc.$2K
- plus $14K from 28 others
What the payments were for
- Consulting fees$6,8759%
- Speaking & faculty fees$34,99245%
- Travel & lodging$10,39513%
- Food & beverage$25,00832%
- Education$4631%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 268 | $26,406 |
| UCB, Inc. | 69 | $23,273 |
| Pfizer | 87 | $4,613 |
| Arcutis Biotherapeutics, Inc. | 25 | $4,479 |
| Johnson & Johnson | 137 | $3,307 |
| Sun Pharmaceutical Industries Inc. | 83 | $1,989 |
| Lilly USA, LLC | 91 | $1,849 |
| Dermavant Sciences, Inc. | 52 | $1,786 |
| Amgen | 78 | $1,583 |
| Novartis | 110 | $1,574 |
| LEO Pharma Inc. | 63 | $1,408 |
| Incyte Corporation | 54 | $1,090 |
| E.r. Squibb & Sons, L.L.C. | 57 | $983 |
| Regeneron Healthcare Solutions, Inc. | 35 | $784 |
| Sanofi | 24 | $500 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 18 | $437 |
| Galderma Laboratories, L.p. | 33 | $412 |
| Organogenesis Inc. | 8 | $245 |
| EPI Health, LLC | 13 | $223 |
| Organon | 8 | $199 |
| Janssen Scientific Affairs, LLC | 3 | $118 |
| Boehringer Ingelheim | 4 | $74 |
| Genentech USA, Inc. | 4 | $73 |
| Almirall LLC | 4 | $68 |
| VYNE Pharmaceuticals Inc. | 3 | $62 |
| Mayne Pharma Commercial LLC | 2 | $43 |
| Journey Medical Corporation | 2 | $34 |
| Vertex | 1 | $25 |
| Biofrontera Inc. | 1 | $19 |
| Cranial Technologies, Inc | 1 | $17 |
| Botanix SB Inc | 1 | $17 |
| Verrica Pharmaceuticals Inc. | 1 | $16 |
| Cipher Pharmaceuticals US LLC | 1 | $14 |
| Biowound Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$77,734 in reported general payments places this provider in the 95th percentile of 384 medical providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 27 | $565,666 |
| Dupixent PenDupilumab | 107 | $531,462 |
| Humira(Cf) PenAdalimumab | 32 | $319,399 |
| Cosentyx Unoready PenSecukinumab | 24 | $208,192 |
| TremfyaGuselkumab | 12 | $158,679 |
| Cyltezo(Cf)Adalimumab-Adbm | 11 | $155,704 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 13 | $111,785 |
| SotyktuDeucravacitinib | 14 | $87,472 |
| Fluorouracil | 226 | $13,813 |
| OraceaDoxycycline Monohydrate | 11 | $9,782 |
| Tacrolimus | 38 | $5,575 |
| Clobetasol Propionate | 122 | $3,990 |
| Ketoconazole | 216 | $3,401 |
| Metronidazole | 67 | $3,283 |
| Ammonium Lactate | 123 | $2,973 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $3,307 | $158,67912 claims |
| Boehringer IngelheimCyltezo(Cf) | $74 | $155,70411 claims |
| E.r. Squibb & Sons, L.L.C.Sotyktu | $983 | $87,47214 claims |
| Galderma Laboratories, L.p.Oracea | $412 | $9,78211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 384 medical providers in South Carolina.
Other medical in Spartanburg
- Ethan CaseySpartanburg$24K
- Kendall SymsSpartanburg$5K
- Laura BuchGreenville$73K
- Suzanne SmithWest Columbia$39K
- Stavros ChrysostomidesColumbia$39K
- Jessica HallColumbia$22K
- Mary MacdonaldCharleston$20K
- Cameron PappasGreenville$18K
- Leslie RumbautGrenville$18K
- Claire DukeGreenville$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.